In addition, a retrospective analysis of lymph-node-positive breast cancer patients, randomized to receive metronomic cyclophosphamide plus methotrexate (CM) chemotherapy or no chemotherapy after completion of standard adjuvant treatments, confirmed CDK12 expression as a valuable biomarker in breast cancer patients [22]. This evidence concerns the gene CDK12 and breast cancer.